Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Liabilities and Shareholders Equity (2020 - 2025)

BioAtla (BCAB) has 6 years of Liabilities and Shareholders Equity data on record, last reported at $15.9 million in Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity fell 74.44% year-over-year to $15.9 million; the TTM value through Sep 2025 reached $133.7 million, down 60.63%, while the annual FY2024 figure was $52.4 million, 56.19% down from the prior year.
  • Liabilities and Shareholders Equity reached $15.9 million in Q3 2025 per BCAB's latest filing, down from $27.1 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $277.6 million in Q3 2021 and bottomed at $15.9 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $149.8 million, with a median of $179.6 million recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: increased 3.87% in 2021, then plummeted 74.44% in 2025.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $254.4 million in 2021, then dropped by 11.27% to $225.7 million in 2022, then plummeted by 46.99% to $119.7 million in 2023, then plummeted by 56.19% to $52.4 million in 2024, then plummeted by 69.65% to $15.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $15.9 million in Q3 2025, $27.1 million in Q2 2025, and $38.3 million in Q1 2025.